Evaluation of the efficacy and prediction of the visual prognosis concerning intravitreal injection of aflibercept for retinal vein occlusion

Evaluation of the efficacy and prediction of the visual prognosis concerning intravitreal injection of aflibercept for retinal vein occlusion - Efficacy of intravitreal injection of aflibercept for retinal vein occlusion

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015162

Enrollment

Registered

2014-09-16

Start date

2014-09-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinal vein occulusion

Interventions

interavitreal injection of 2.0mg of aflibercept

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with visual impairments due to macular edema associated with retinal vein oclusion

Exclusion criteria

Exclusion criteria: Patients with difficulty in intravitreal injection and examination because of mental retardation or dementia

Design outcomes

Primary

Measure	Time frame
Analysis of the factor concerning the variation of best-corrected visual acuity 1 year after the first intravitreal injection	—

Secondary

Measure	Time frame
Analysis of the factor concerning the variation of best-corrected visual acuity and the regression of macular edema 2 year after the first intravitreal injection	—

Countries

Japan

Contacts

Public ContactYuki Muraoka

Kyoto University Graduate School of Medicine Department of Ophthalmology and Visual Sciences

muraoka@kuhp.kyoto-u.ac.jp075-751-3248

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026